CN102399220A - Tricyclic dual PI3K and mTOR inhibitors - Google Patents
Tricyclic dual PI3K and mTOR inhibitors Download PDFInfo
- Publication number
- CN102399220A CN102399220A CN2010102824065A CN201010282406A CN102399220A CN 102399220 A CN102399220 A CN 102399220A CN 2010102824065 A CN2010102824065 A CN 2010102824065A CN 201010282406 A CN201010282406 A CN 201010282406A CN 102399220 A CN102399220 A CN 102399220A
- Authority
- CN
- China
- Prior art keywords
- substituted
- methyl
- alkyl
- naphthyridines
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)(C)OC(N(CC1)CCC1NC(C(C=O)=C*1)=C(*2)C1=CC=C2c1cc(C=N)c(NCc(cc2)ccc2OC)nc1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1NC(C(C=O)=C*1)=C(*2)C1=CC=C2c1cc(C=N)c(NCc(cc2)ccc2OC)nc1)=O 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention which belongs to the technical field of medicines concretely relates to tricyclic dual PI3K and mTOR inhibitors with a general formula represented by formula (I), pharmaceutically acceptable salts thereof, or stereoisomers thereof. In the formula (I), R<1>, R<2>, R<3>, R<4>, R<5>, R<6>, X, A, and B are defined in the specification. The invention also relates to a preparation method of above compounds, a medicinal preparation containing the compounds, and an application of the compounds in the preparation of medicines for treating and/or preventing proliferative diseases responding to the inhibition of the activity of lipase and/or PI3-kinase-related protein kinase, especially the PI3 kinase and/or mTOR.
Description
1, technical field
The invention belongs to medical technical field; Be specifically related to three and lopps PI3K and mTOR double inhibitor, its pharmacy acceptable salt or its steric isomer; The preparation method of these compounds; The pharmaceutical prepn that contains these compounds, and these compounds treat and/or prevent the application in the medicine of the proliferative disease that lipase and/or PI3-kinases-dependency protein kinase, particularly PI3 kinases and/or the active inhibition of mTOR is had response in preparation.
2, background technology
Tumour be body under the effect of the various tumorigenesis factor, cause the cytogenetics substance change, cause genetic expression not normal, cellular abnormality propagation and the true tumor that forms.Tumour cell loses the normal growth regulatory function, has independently or autonomous relatively energy for growth, still can continued growth after the tumorigenesis factor stops, and the nutritive substance of mass consumption human body.If find and treat untimely, cancer cells also can be transferred to whole body growth and breeding everywhere, and discharges multiple toxin, causes that human body is become thin, anaemia, organ function is impaired and even dead.
The method of treatment tumour mainly comprises three aspects: pharmacological agent, operative treatment and radiotherapy.Because operative treatment, radiotherapy are difficult to thoroughly eradicate tumour, and the effect of centering patients with advanced cancer is not obvious, so the status of pharmacological agent in oncotherapy is more and more obvious.The traditional antineoplastic thing can't be distinguished tumour cell and normal tissue cell; Often cause severe side effect, targeted drug as the specificity target spot, can accurately act on tumour with cancer cells; Improved treatment level greatly; And reduced the untoward reaction rate, for example make the median survival time of advanced CRC increase by 66.7%, the efficient raising 71.3% of the treatment of advanced breast cancer.
Because it is sought-after to the antitumour drug of this classification that each drugmaker, adds market to the development acceleration of target class antitumour drug, molecular targeted agents has become fastest-rising unit in the global antitumor drug market.The PI3K path is the place of the most often morphing among the human cancer cell, can cause cell proliferation, activation, amplifying signal.PI 3 kinases (PI3K) and Mammals rapamycin target protein (mTOR) are the important kinases of PI3K signal path.
PI 3 kinases (PI3K) are fat kinases family members, can produce PI triphosphoric acid fat (PIP3) through 3 phosphorylations of phosphatidyl alcohol and regulate cellular metabolism and growth.The second messenger PIP3 of this lipid can make P13K combine with effector (particularly Akt) pairing in downstream, thereby causes film to be raised and phosphorylation, cell proliferation, activation.Therefore inhibition of phosphatidylinositol3 3 kinases can influence the PI3K path, thus anticancer propagation, activation.
MTOR is a kind of protein serine/threonine that is present in the endochylema; Belong to phosphoinositide kinase-associated protein kinases family; Form with two kinds of mixtures exists in vivo, i.e. mTORC1 (action target spot of rapamycin) and mTORC2 (not suppressed by rapamycin).MTOR is a kind of cell signalling albumen, and its regulate tumor cell is to the reaction of nutrient and growth factor, and through the blood supply to the effect control tumour of VEGF.The mTOR suppressor factor can make cancer cells hungry, and through the effect that suppresses mTOR gross tumor volume is dwindled.
Among patent WO2006122806 of Novartis and the patent WO2010038165 of Pfizer, all reported the validity of PI3K/mTOR double inhibitor in oncotherapy.At present, do not have the listing of PI3K/mTOR double inhibitor class medicine temporarily, therefore, need the more PI3K/mTOR double inhibitor structure type of research and development, so that select validity and better security compound to be used for treatment for cancer.
3, summary of the invention
The object of the present invention is to provide a kind of PI3K and mTOR double inhibitor.
Technical scheme of the present invention is following:
Wherein
X is a Sauerstoffatom, sulphur atom, or NR
15
A is a nitrogen-atoms, or CR
7
B is a nitrogen-atoms, or CR
8
R
1Be Wasserstoffatoms, or be not substituted or choose wantonly by 1-5 R
9Substituted C
1-6Alkyl, C
3-8Naphthenic base, C
3-8Thiazolinyl, C
3-8Alkynyl, aryl, heterocyclic radical;
R
2Be Wasserstoffatoms, or be not substituted or choose wantonly by 1-5 R
9Substituted C
1-6Alkyl, C
3-8Naphthenic base, C
2-8Thiazolinyl, C
2-8Alkynyl, aryl, heterocyclic radical;
R
3Be Wasserstoffatoms, hydroxyl, carboxyl ,-(CH
2)
nNR
10aR
10b,-(CH
2)
nC (O) R
11,-(CH
2)
nS (O)
mR
11,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11,-(CH
2)
nC (O) (CH
2)
nNR
10aR
10b,-(CH
2)
nOC (O) R
11,-(CH
2)
nC (O) OR
11,-(CH
2)
nNR
10aC (O) R
11,-(CH
2)
nNR
10aC (O) NR
10aR
10b, or be not substituted or choose wantonly individual halogen atom, hydroxyl, the substituted C of carboxyl substituent of being selected from by 1-3
1-6Alkyl, C
1-6Alkoxyl group;
R
4, R
6Be Wasserstoffatoms independently respectively, or be not substituted or choose wantonly by 1-3 R
9Substituted C
1-6Alkyl, or R
4And R
6Be interconnected to form C
3-8Naphthenic base or heterocyclic radical;
R
5Be Wasserstoffatoms ,-(CH
2)
nS (O)
mR
11, or be not substituted or choose wantonly by 1-3 R
9Substituted C
1-6Alkyl;
R
7, R
8Independently be Wasserstoffatoms respectively, halogen atom, cyanic acid, hydroxyl, carboxyl ,-(CH
2)
nNR
10aR
10b,-(CH
2)
nC (O) R
11,-(CH
2)
nS (O)
mR
11,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11,-(CH
2)
nC (O) (CH
2)
nNR
10aR
10b,-(CH
2)
nOC (O) R
11,-(CH
2)
nC (O) OR
11,-(CH
2)
nNR
10aC (O) R
11,-(CH
2)
nNR
10aC (O) NR
10aR
10b, or be not substituted or choose wantonly individual halogen atom, hydroxyl, the substituted C of carboxyl substituent of being selected from by 1-3
1-6Alkyl, C
1-6Alkoxyl group;
R
9Be halogen atom, hydroxyl, cyanic acid, carboxyl ,-(CH
2)
nNR
10aR
10b,-(CH
2)
nC (O) R
11,-(CH
2)
nS (O)
mR
11,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11,-(CH
2)
nC (O) (CH
2)
nNR
10aR
10b,-(CH
2)
nOC (O) R
11,-(CH
2)
nC (O) OR
11,-(CH
2)
nNR
10aC (O) R
11,-(CH
2)
nNR
10aC (O) NR
10aR
10b, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
2-8Thiazolinyl, C
2-8Alkynyl, C
1-6Alkoxyl group, C
3-8Naphthenic base, aryl, heterocyclic radical;
R
10a, R
10bBe Wasserstoffatoms independently respectively, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
3-8Naphthenic base, aryl, heterocyclic radical;
R
11For not being substituted or choosing wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-8Naphthenic base, aryl, heterocyclic radical;
R
12Be hydroxyl, halogen atom, cyanic acid, trifluoromethyl, C
1-6Alkyl, C
2-8Thiazolinyl, C
2-8Alkynyl, C
1-6Alkoxyl group, C
3-8Naphthenic base, aryl, heterocyclic radical ,-(CH
2)
nNR
13aR
13b,-(CH
2)
nC (O) R
14,-(CH
2)
nC (O) NR
13aR
13b,-(CH
2)
nS (O)
mR
14,-(CH
2)
nS (O)
mNR
13aR
13b,-(CH
2)
nNR
13aS (O)
mR
14,-(CH
2)
nOC (O) R
14,-(CH
2)
nNR
13aC (O) R
14, or-(CH
2)
nNR
13aC (O) NR
13aR
13b
R
13a, R
13bIndependently be Wasserstoffatoms respectively, C
1-6Alkyl, C
3-8Naphthenic base, aryl, or heterocyclic radical;
R
14Be C
1-6Alkyl, C
3-8Naphthenic base, aryl, or heterocyclic radical;
R
15Be Wasserstoffatoms, or C
1-6Alkyl;
M is 1 or 2;
N is 0～4.
Preferred compound is:
Wherein
X is a Sauerstoffatom;
A is CR
7
B is CR
8
R
1For not being substituted or choosing wantonly by 1-3 R
9Substituted C
1-6Alkyl, C
3-8Naphthenic base, aryl, 4-10 unit heterocyclic radical;
R
2For not being substituted or choosing wantonly by 1-3 R
9Substituted C
1-6Alkyl, C
3-8Naphthenic base, aryl, 4-10 unit heterocyclic radical;
R
3Be Wasserstoffatoms ,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11, or be not substituted or choose wantonly individual halogen atom, hydroxyl, the substituted C of carboxyl substituent of being selected from by 1-3
1-6Alkyl, C
1-6Alkoxyl group;
R
4, R
6Be Wasserstoffatoms independently respectively, or be not substituted or choose wantonly by 1-3 R
9Substituted C
1-6Alkyl, or R
4With R
6Be interconnected to form C
3-6Naphthenic base or 3～7 yuan of saturated heterocyclic radicals;
R
5Be Wasserstoffatoms, or be not substituted or choose wantonly by 1-3 R
9Substituted C
1-6Alkyl;
R
7, R
8Independently be Wasserstoffatoms respectively ,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11, or be not substituted or choose wantonly individual halogen atom, hydroxyl, the substituted C of carboxyl substituent of being selected from by 1-3
1-6Alkyl, C
1-6Alkoxyl group;
R
9Be halogen atom, hydroxyl ,-(CH
2)
nNR
10aR
10b,-(CH
2)
nC (O) R
11,-(CH
2)
nS (O)
mR
11,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11,-(CH
2)
nC (O) (CH
2)
nNR
10aR
10b,-(CH
2)
nOC (O) R
11,-(CH
2)
nC (O) OR
11,-(CH
2)
nNR
10aC (O) R
11,-(CH
2)
nNR
10aC (O) NR
10aR
10b, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-8Naphthenic base, aryl, 4-10 unit heterocyclic radical;
R
10a, R
10bBe Wasserstoffatoms independently respectively, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-6Alkyl;
R
11For not being substituted or choosing wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-8Naphthenic base, aryl, 4-10 unit heterocyclic radical;
R
12Be hydroxyl, halogen atom, cyanic acid, trifluoromethyl, C
1-6Alkyl, C
2-8Thiazolinyl, C
2-8Alkynyl, C
1-6Alkoxyl group, C
3-8Naphthenic base, aryl, 4-10 unit heterocyclic radical, or-(CH
2)
nNR
13aR
13b
R
13a, R
13bIndependently be Wasserstoffatoms respectively, C
1-6Alkyl, C
3-8Naphthenic base, aryl, or 4-10 unit heterocyclic radical;
M is 1 or 2;
N is 0～4.
Preferred compound is:
Wherein
X is a Sauerstoffatom;
A is CR
7
B is CR
8
R
1For not being substituted or choosing wantonly by 1-3 R
9Substituted C
1-6Alkyl, C
3-7Naphthenic base, phenyl, naphthyl, 5-10 unit heterocyclic radical;
R
2For not being substituted or choosing wantonly by 1-3 R
9Substituted phenyl, naphthyl, 5-10 unit heterocyclic radical;
R
3, R
4, R
6, R
7, R
8Be respectively Wasserstoffatoms;
R
5Be Wasserstoffatoms, or be not substituted or choose wantonly by 1-3 R
9Substituted C
1-6Alkyl;
R
9Be halogen atom, hydroxyl ,-(CH
2)
nNR
10aR
10b,-(CH
2)
nC (O) R
11,-(CH
2)
nS (O)
mR
11,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11,-(CH
2)
nC (O) (CH
2)
nNR
10aR
10b,-(CH
2)
nOC (O) R
11,-(CH
2)
nC (O) OR
11,-(CH
2)
nNR
10aC (O) R
11,-(CH
2)
nNR
10aC (O) NR
10aR
10b, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-7Naphthenic base, phenyl, 5-10 unit heterocyclic radical;
R
10a, R
10bBe Wasserstoffatoms independently respectively, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-6Alkyl;
R
11For not being substituted or choosing wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-7Naphthenic base, phenyl, 5-10 unit heterocyclic radical;
R
12Be hydroxyl, halogen atom, cyanic acid, trifluoromethyl, C
1-6Alkyl, C
1-6Alkoxyl group, C
3-7Naphthenic base, phenyl, 5-10 unit heterocyclic radical, or-(CH
2)
nNR
13aR
13b
R
13a, R
13bIndependently be Wasserstoffatoms respectively, C
1-6Alkyl, C
3-7Naphthenic base, phenyl, or 5-10 unit heterocyclic radical;
M is 1 or 2;
N is 0～3.
Preferred compound is:
Wherein
X is a Sauerstoffatom;
A is CR
7
B is CR
8
R
1For not being substituted or choosing wantonly by 1-3 R
9Substituted cyclopentyl, cyclohexyl, phenyl, naphthyl, piperidyl, piperazinyl, imidazolidyl, pyrazolidyl, tetrahydrofuran base, morpholinyl, pyridyl, pyrimidyl, pyrazolyl, indazolyl, quinolyl, indyl, Pyrazolopyridine base;
R
2For not being substituted or choosing wantonly by 1-3 R
9Substituted phenyl, pyridyl, pyrimidyl, pyrazolyl, indazolyl, quinolyl, indyl, Pyrazolopyridine base;
R
3, R
4, R
6, R
7, R
8Be respectively Wasserstoffatoms;
R
5Be Wasserstoffatoms, or be not substituted or choose wantonly by 1-3 R
9Substituted C
1-6Alkyl;
R
9Be halogen atom, hydroxyl ,-(CH
2)
nNR
10aR
10b,-(CH
2)
nC (O) R
11,-(CH
2)
nS (O)
mR
11,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11,-(CH
2)
nC (O) (CH
2)
nNR
10aR
10b,-(CH
2)
nOC (O) R
11,-(CH
2)
nC (O) OR
11,-(CH
2)
nNR
10aC (O) R
11,-(CH
2)
nNR
10aC (O) NR
10aR
10b, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-6Naphthenic base, 5-7 unit heterocyclic radical;
R
10a, R
10bIndependently be Wasserstoffatoms respectively, methyl, or ethyl;
R
11For not being substituted or choosing wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-6Naphthenic base, phenyl, 5-7 unit heterocyclic radical;
R
12Be hydroxyl, fluorine atom, cyanic acid, trifluoromethyl, C
1-6Alkyl, C
1-6Alkoxyl group, or-(CH
2)
nNR
13aR
13b
R
13a, R
13bIndependently be Wasserstoffatoms respectively, methyl, or ethyl;
M is 1 or 2;
N is 0～3.
Preferred compound is:
Wherein
X is a Sauerstoffatom;
A is CR
7
B is CR
8
R
1For not being substituted or choosing wantonly by 1-3 R
9Substituted cyclopentyl, cyclohexyl, phenyl, naphthyl, piperidyl, piperazinyl, morpholinyl, pyridyl, pyrimidyl, pyrazolyl, indazolyl, quinolyl, indyl, Pyrazolopyridine base;
R
2For not being substituted or choosing wantonly by 1-3 R
9Substituted phenyl, pyridyl, pyrimidyl, indazolyl, quinolyl, indyl, Pyrazolopyridine base;
R
3, R
4, R
6, R
7, R
8Be respectively Wasserstoffatoms;
R
5Be Wasserstoffatoms, methyl, ethyl, or propyl group;
R
9Be fluorine atom, chlorine atom, hydroxyl ,-(CH
2)
nNR
10aR
10b,-(CH
2)
nC (O) R
11,-(CH
2)
nS (O)
mR
11,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11,-(CH
2)
nC (O) (CH
2)
nNR
10aR
10b,-(CH
2)
nOC (O) R
11,-(CH
2)
nC (O) OR
11,-(CH
2)
nNR
10aC (O) R
11,-(CH
2)
nNR
10aC (O) NR
10aR
10b, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-6Naphthenic base, piperazinyl, imidazolyl, pyrazolyl, triazolyl;
R
10a, R
10bIndependently be Wasserstoffatoms respectively, methyl, or ethyl;
R
11For not being substituted or choosing wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-6Naphthenic base, phenyl;
R
12Be hydroxyl, fluorine atom, cyanic acid, trifluoromethyl, C
1-6Alkyl, C
1-6Alkoxyl group, or-(CH
2)
nNR
13aR
13b
R
13a, R
13bIndependently be Wasserstoffatoms respectively, methyl, or ethyl;
M is 1 or 2;
N is 0～3.
Preferred compound is:
Wherein
X is a Sauerstoffatom;
A is CR
7
B is CR
8
R
1For not being substituted or choosing wantonly by 1-3 R
9Substituted cyclopentyl, cyclohexyl, phenyl, piperidyl, piperazinyl, morpholinyl, pyridyl, pyrimidyl, indazolyl, quinolyl, indyl, Pyrazolopyridine base;
R
2For not being substituted or choosing wantonly by 1-3 R
9Substituted phenyl, pyridyl, pyrimidyl, indazolyl, quinolyl, indyl, Pyrazolopyridine base;
R
3, R
4, R
6, R
7, R
8Be respectively Wasserstoffatoms;
R
5Be Wasserstoffatoms, methyl, ethyl, or propyl group;
R
9Be fluorine atom, chlorine atom, hydroxyl ,-(CH
2)
nNR
10aR
10b,-(CH
2)
nC (O) R
11,-(CH
2)
nS (O)
mR
11,-(CH
2)
nC (O) (CH
2)
nNR
10aR
10b,-(CH
2)
nOC (O) R
11,-(CH
2)
nC (O) OR
11,-(CH
2)
nNR
10aC (O) R
11,-(CH
2)
nNR
10aC (O) NR
10aR
10b, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-3Alkyl, C
1-2Alkoxyl group, C
3-6Naphthenic base, piperazinyl, imidazolyl, pyrazolyl;
R
10a, R
10bIndependent respectively is Wasserstoffatoms, methyl, or ethyl;
R
11For not being substituted or choosing wantonly by 1-3 R
12Substituted C
1-4Alkyl, C
1-3Alkoxyl group, phenyl;
R
12Be hydroxyl, fluorine atom, cyanic acid, trifluoromethyl, methyl, ethyl, sec.-propyl, methoxyl group, or oxyethyl group;
M is 1 or 2;
N is 0～2.
Part of compounds of the present invention:
" halogen atom " of the present invention comprises fluorine atom, chlorine atom, bromine atoms, iodine atom.
" C of the present invention
1-6Alkyl " hydrocarbon that refers to contain 1～6 carbon atom partly removes the alkyl of a Wasserstoffatoms deutero-straight or branched, like methyl, ethyl, propyl group, 1-methylethyl, butyl, 1-methyl-propyl, 2-methyl-propyl, 1,1-dimethyl ethyl, amyl group, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1; 1-dimethyl propyl, 1,2-dimethyl propyl, 2,2-dimethyl propyl, 1-ethyl propyl, hexyl, 1-methyl amyl, 2-methyl amyl, 3-methyl amyl, 4-methyl amyl, 1; 1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2; 2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethyl-butyl, 2-ethyl-butyl, 1; 1; 2-trimethylammonium propyl group, 1,2,2-trimethylammonium propyl group, 1-ethyl-1-methyl-propyl and 1-ethyl-2-methyl-propyl." C of the present invention
1-4Alkyl ", " C
1-3Alkyl " refer to the specific examples that contains 1～4,1～3 carbon atom in the above-mentioned instance respectively.
" C of the present invention
3-8Naphthenic base " refer to contain the cyclic alkyl of 3～8 carbon atoms, like Trimetylene base, tetramethylene base, pentamethylene base, cyclohexyl, suberane, cyclooctane etc." C of the present invention
3-7Naphthenic base ", " C
3-6Naphthenic base " refer to the specific examples that contains 3～7,3～6 carbon atoms in the above-mentioned instance respectively.
" C of the present invention
2-8Thiazolinyl " be meant that the carbonatoms that contains two keys is 2～8 straight or branched or cyclic thiazolinyl, like vinyl, 1-propenyl, 2-propenyl, 1-methyl ethylene, 1-butylene base, crotyl, 3-crotonyl, 1-methyl isophthalic acid-propenyl, 2-methyl isophthalic acid-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl isophthalic acid-crotonyl, 2-methyl-1-butene thiazolinyl, 3-methyl-1-butene base, 1-methyl-2-butene base, 2-methyl-2-butene base, 3-methyl-2-butene base, 1-methyl-3-crotonyl, 2-methyl-3-crotonyl, 3-methyl-3-crotonyl, 1,1-dimethyl--2-propenyl, 1; 2-dimethyl--1-propenyl, 1,2-dimethyl--2-propenyl, 1-ethyl-1-propenyl, 1-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentene thiazolinyl, 2-methyl-1-pentene thiazolinyl, 3-methyl-1-pentene thiazolinyl, 4-methyl-1-pentene base, 1-methyl-pentenyl, 2-methyl-pentenyl, 3-methyl-pentenyl, 4-methyl-pentenyl, 1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1,1-dimethyl--crotyl, 1; 1-dimethyl--3-crotonyl, 1; 2-dimethyl--1-butylene base, 1,2-dimethyl--crotyl, 1,2-dimethyl--3-crotonyl, 1; 3-dimethyl--1-butylene base, 1; 3-dimethyl--crotyl, 1,3-dimethyl--crotyl, 2,2-dimethyl--3-crotonyl, 2; 3-dimethyl--1-butylene base, 2; 3-dimethyl--crotyl, 2,3-dimethyl--3-crotonyl, 3,3-dimethyl--1-butylene base, 3; 3-dimethyl--crotyl, 1-ethyl-1-butylene base, 1-ethyl-crotyl, 1-ethyl-3-crotonyl, 2-ethyl-1-butylene base, 2-ethyl-crotyl, 2-ethyl-3-crotonyl, 1; 1,2-trimethylammonium-2-propenyl, 1-ethyl-1-methyl-2-propenyl, 1-ethyl-2-methyl isophthalic acid-propenyl, 1-ethyl-2-methyl-2-propenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 4-octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1,3-butadiene base, 1; 3-pentadienyl, 1; 4-pentadienyl, 2,4-pentadienyl, 1,4-hexadienyl, 2; 4-hexadienyl, 1; 5-heptadiene base, 1,6-heptadiene base, 2,5-heptadiene base, 1; 6-octadienyl, 1; 7-octadienyl, 2,6-octadienyl, 2,7-octadienyl, cyclopentenyl, 1; 3-cyclopentadienyl moiety, cyclohexenyl, 1; 4-cyclohexadienyl, cycloheptenyl, 1,4-cycloheptadiene base, cyclooctene base and 1,5-cyclooctadiene base etc.Two keys can randomly be cis and trans." C of the present invention
3-8Thiazolinyl " be meant the specific examples that contains 3～8 carbon atoms in the above-mentioned instance.
" C of the present invention
2-8Alkynyl " be meant and contain the alkynyl that the triple-linked carbonatoms is 2～8 straight or branched; like ethynyl, 1-proyl, 2-propynyl, 2-butyne base, 3-butynyl, 1-methyl-2-propynyl, valerylene base, 3-pentynyl, 4-pentynyl, 1-methyl-2-butyne base, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 1; 1-dimethyl--2-propynyl, 1-ethyl-2-propynyl, 2-hexyn, 3-hexyn, 4-hexyn, 5-hexyn, 1-methyl-valerylene base, 4-methyl-valerylene base, 1-methyl-3-pentynyl, 2-methyl-3-pentynyl, 1-methyl-4-pentynyl, 2-methyl-4-pentynyl, 3-methyl-4-pentynyl, 1; 1-dimethyl--2-butyne base, 1; 1-dimethyl--3-butynyl, 1; 2-dimethyl--3-butynyl, 2,2-dimethyl--3-butynyl, 1-ethyl-2-butyne base, 1-ethyl-3-butynyl, 2-ethyl-3-butynyl, 1-ethyl-1-methyl-2-propynyl, 2-heptyne base, 3-heptyne base, 4-heptyne base, 5-heptyne base, 6-heptyne base, 1-methyl-2-hexyn, 4-methyl-2-hexyn, 5-methyl-2-hexyn, 1-methyl-3-hexyn, 2-methyl-3-hexyn, 5-methyl-3-hexyn, 1-methyl-4-hexyn, 2-methyl-4-hexyn, 3-methyl-4-hexyn, 1-methyl-5-hexyn, 2-methyl-5-hexyn, 3-methyl-5-hexyn, 4-methyl-5-hexyn, 2-octyne base, 3-octyne base, 4-octyne base, 5-octyne base, 6-octyne base, 7-octyne base, 1-methyl-2-heptyne base, 4-methyl-2-heptyne base, 5-methyl-2-heptyne base, 6-methyl-2-heptyne base, 1-methyl-3-heptyne base, 2-methyl-3-heptyne base, 5-methyl-3-heptyne base, 6-methyl-3-heptyne base, 1-methyl-4-heptyne base, 2-methyl-4-heptyne base, 3-methyl-4-heptyne base, 6-methyl-4-heptyne base, 1-methyl-5-heptyne base, 2-methyl-5-heptyne base, 3-methyl-5-heptyne base, 4-methyl-5-heptyne base, 1-methyl-6-heptyne base, 2-methyl-6-heptyne base, 3-methyl-6-heptyne base, 4-methyl-6-heptyne base and 5-methyl-6-heptyne base etc." C of the present invention
3-8Alkynyl " be meant the specific examples that contains 3～8 carbon atoms in the above-mentioned instance.
" C of the present invention
1-6Alkoxyl group " refer to " C
1-6Alkyl " group that is connected with other structures through Sauerstoffatom, like methoxyl group, oxyethyl group, propoxy-, 1-methyl ethoxy, butoxy, 1-methyl propoxy-, 2-methyl propoxy-, 1,1-dimethyl-oxyethyl group, pentyloxy, 1-methyl butoxy, 2-methyl butoxy, 3-methyl butoxy, 1; 1-dimethyl-propoxy-, 1,2-dimethyl-propoxy-, 2,2-dimethyl-propoxy-, 1-ethyl propoxy-, hexyloxy, 1-methyl pentyloxy, 2-methyl pentyloxy, 3-methyl pentyloxy, 4-methyl pentyloxy, 1; 1-dimethyl-butoxy, 1; 2-dimethyl-butoxy, 1,3-dimethyl-butoxy, 2,2-dimethyl-butoxy, 2; 3-dimethyl-butoxy, 3; 3-dimethyl-butoxy, 1-ethyl butoxy, 2-ethyl butoxy, 1,1,2-trimethylammonium propoxy-, 1; 2,2-trimethylammonium propoxy-, 1-ethyl-1-methyl propoxy-and 1-ethyl-2-methyl propoxy-.Term " C
1-3Alkoxyl group ", " C
1-2Alkoxyl group " refer to the specific examples that contains 1～3,1～2 carbon atom in the above-mentioned instance respectively.
" aryl " of the present invention is meant monocycle or the bicyclic carbocyclic system with one or two aromatic ring, includes but not limited to phenyl, naphthyl, tetralyl, 2,3-indanyl, indenyl etc.
" heterocyclic radical " of the present invention is meant and contains one or more heteroatomic 3～14 yuan of cyclic groups, and said " heteroatoms " is meant nitrogen-atoms, Sauerstoffatom, sulphur atom etc." heterocyclic radical " saturated or undersaturated single heterocyclic radical and saturated or undersaturated fused heterocycle base.
The instance of described " saturated or undersaturated single heterocyclic radical " has: Oxyranyle, dioxirane base, thiirane base, ethylenimine base, 2H-ethylenimine base, diazacyclo propyl, 3H-diazacyclo propenyl, oxaza propyl, oxetanyl, 1,2-dioxetanes alkyl, Thietane base, 1,2-dithia cyclobutene base, azetidinyl, 1,2-diazetidine base, azete base, 1,2-diazetine base, furyl, tetrahydrofuran base, thienyl, 2; 5-dihydro-thiophene base, tetrahydro-thienyl, pyrryl, pyrrolin base, pyrrolidyl, 1,3-dioxolane base, 1,3-dioxole-2-ketone group, 1,2-dithia cyclopentenyl, 1; 3-dithiolane base, imidazolyl, 4,5-glyoxalidine base, imidazolidyl, pyrazolyl, 4,5-pyrazoline base, pyrazolidyl 、 oxazolyl, 4,5-dihydro-oxazole base 、 isoxazolyl, 4; 5-dihydro-isoxazole base, 2,3-dihydro-isoxazole base, 1,2,3-oxadiazole base, 1; 2,5-oxadiazole base, thiazolyl, 4,5-dihydro-thiazolyl, isothiazolyl, 1,2; 3-thiadiazolyl group, 1,2,4-thiadiazolyl group, 1,3; 4-thiadiazolyl group, 1,2,3-triazoles base, 1,2; 4-triazolyl, tetrazyl, 2H-pyranyl, 2H-pyran-2-one base, 3,4-dihydro-2H-pyranyl, 4H-pyranyl, THP trtrahydropyranyl, 4H-pyrans-4-ketone group, pyridyl, 2-pyriconyl, 4-pyriconyl, piperidyl, 1,4-Dioxin base, 1,4-dithia cyclohexadienyl, 1; 4-oxathiin base, 1,4-dioxane base, 1,3 dioxane base, 1,3-oxathiane base, 2H-1; 2-oxazinyl, 4H-1,2-oxazinyl, 6H-1,2-oxazinyl, 2H-1,3-oxazinyl, 4H-1; 3-oxazinyl, 6H-1,3-oxazinyl, 2H-1,4-oxazinyl, 4H-1,4-oxazinyl, 5; 6-dihydro-4H-1,3-oxazinyl, morpholinyl, 2H-1,3-thiazinyl, 4H-1,3-thiazinyl, 5; 6-dihydro-4H-1,3-thiazinyl, 6H-1,3-thiazinyl, 2H-1,4-thiazinyl, 4H-1; 4-thiazinyl, pyridazinyl, pyrimidyl, pyrazinyl, piperazinyl, 1,2,3-triazinyl, 1,2; 4-triazinyl, 1,3,5-triazines base, 1,2; 4,5-tetrazine base, oxepin base, thia cycloheptatriene base, 1,4-dioxane sarohornene base, nitrogen heterocyclic heptantriene base, 1,2-diazacyclo heptantriene base, 1; 3-diazacyclo heptantriene base, 1,4-diazacyclo heptantriene base, nitrogen heterocyclic octatetraene base, 1,4-dihydro-1,4-diazocine trialkenyl etc.
The instance of described " saturated or undersaturated fused heterocycle base " has: benzofuryl, isobenzofuran-base, dibenzofuran group, benzo [b] thienyl, benzo [c] thienyl, indyl, pseudoindoyl, carbazyl, benzoxazolyl, benzothiazolyl, benzimidazolyl-, indazolyl, benzotriazole base, 2H-chromogen thiazolinyl, 2H-chromogen alkene-2-ketone group, 4H-chromenyl, 4H-chromene-4-ketone group, chromanyl, quinolyl, isoquinolyl, 2-quinoline ketone group, 4-quinoline ketone group, 1-isoquinoline 99.9 ketone group, acridyl, phenanthridinyl, 4H-1,3-benzoxazinyl, phenazinyl, phenothiazinyl, phthalazinyl, cinnolines base, 2,3-dihydro mix naphthalene, quinazolyl, 3; 4-dihydroquinazoline base, purine radicals, 1,8-naphthyridinyl, 1,7-naphthyridinyl, 1; 6-naphthyridinyl, 1,5-naphthyridinyl, 2,7-naphthyridinyl, 2; 6-naphthyridinyl, pteridyl, quinoxalinyl, 1,2-dihydro-quinoxaline base, phenazinyl, imidazolidine be [4,5-c] pyridyl, 3-oxo-1 also; 3-dihydroisobenzofuran base, 4,6-dihydro-1H-furo [3,4-d] imidazolyl, 3a; 4,6,6a-tetrahydrochysene-1H-furo [3; 4-d] imidazolyl, 4,6-dihydro-1H-thieno-[3,4-d] imidazolyl, 4; 6-dihydro-1H-pyrrolo-[3; 4-d] imidazolyl, 4,5,6; 7-tetrahydrochysene-1H-benzo [d] imidazolyl, 1H-pyrazolo [3,4-b] pyridyl etc.
" 4～10 yuan of heterocyclic radicals " of the present invention, " 5～10 yuan of heterocyclic radicals ", " 5～7 yuan of heterocyclic radicals " are meant in above-mentioned " heterocyclic radical " specific examples of the saturated or undersaturated cyclic group of 4～10 yuan, 5～10 yuan, 5～7 yuan respectively." 3～7 yuan of saturated heterocyclic radicals " of the present invention is meant in above-mentioned " heterocyclic radical " specific examples of 3～7 yuan saturated cyclic group.
Above-claimed cpd of the present invention can adopt method and/or known other technology of those of ordinary skills of describing in the following flow process to synthesize, but is not limited only to following method.
Reactions step:
(1) preparation of midbody 1
With raw material 1, raw material 2, palladium catalyst (includes but not limited to Pd (PPh
3)
4, Pd (dppf)
2Cl
2And Pd (PPh
3)
2Cl
2) and alkali (include but not limited to KOAC, K
3PO
4And K
2CO
3) join successively in organic solvent (including but not limited to dioxane, DMSO, DMF and toluene) and the less water, substitute nitrogen, the tube sealing reacting by heating adds shrend and goes out, extraction, drying, column chromatography gets midbody 1.
(2) preparation of midbody 2
Raw material 3 is joined in the alcoholic solution of midbody 1, be heated to backflow, reaction finishes, and revolves dried solvent, and column chromatography gets midbody 2.
(3) preparation of midbody 3
Midbody 2 is dissolved in CH
2Cl
2In, add raw material 4, add little acetic acid and be adjusted to the slightly acidic system, after stirring for some time, add NaBH (OAc) in batches
3, continue to stir, add the NaBH that it is unnecessary that shrend is gone out (OAc)
3, use dichloromethane extraction, concentrate, column chromatography gets midbody 3.
(4) preparation of formula I compound
In the exsiccant reaction flask, add TRIPHOSGENE 99.5, triethylamine is dissolved in the THF; Under the cooling conditions, add midbody 3, stir; Revolve most of THF, use ethyl acetate extraction, with saturated sodium carbonate solution and strong brine washing; Organic layer is used anhydrous sodium sulfate drying, and column chromatography purification gets formula I compound.
In the reaction equation, R
1, R
2, R
3, R
4, R
5, X, A and B such as preamble definition.
In the reaction process, the functional group of the starting compound that should not participate in reacting can exist not report the form of protecting, and perhaps can be protected, then according to all or part of protection base of removing of the method for routine.For example, if there is amino acid proton, " amino protecting group " of available routine protected; The instance of said " amino protecting group " comprising: methyl, ring third methyl, 1-methyl isophthalic acid-ring third methyl, diisopropyl methyl, 9-fluorene methyl, 9-(2-sulfo-) fluorene methyl, furfuryl, 2,2,2-trichloromethyl, 2-halogenated methyl, 5-benzoisoxazole ylmethyl, 9-anthryl methyl, diphenyl-methyl, trityl, two (2-pyridyl) methyl, phenacyl-, methoxymethyl, 2-chloroethoxy methyl, benzyloxymethyl, valeryl methyl, two (p-methoxyphenyl) methyl, (p-methoxyphenyl) diphenyl methyl, ethyl, 2-iodine ethyl, 2-trimethyl silyl ethyl, 2-methylmercaptoethyl, 2-methylsulfonyl ethyl, 2-(p-toluenesulfonyl) ethyl, 2-phosphorus base ethyl, 1-methyl isophthalic acid-(adamantyl) ethyl, 1-methyl isophthalic acid-styroyl, 1-methyl isophthalic acid-(3; The 5-dimethoxy phenyl) ethyl, 1-methyl isophthalic acid-(4-xenyl) ethyl, 1-methyl isophthalic acid-(to the phenylazo-phenyl) ethyl, 1; 1-dimethyl--2,2,2-three chloroethyls, 1; 1-dimethyl--2-cyanoethyl, 1-methyl isophthalic acid-(4-pyridyl) ethyl, 1-(methoxycarbonyl is amino)-2; 2,2, trifluoroethyl, 1-(trifluoromethyl)-1-(to the chlorophenoxy methoxyl group)-2; 2; 2 ,-trifluoroethyl, 1,1-dimethyl--3-(N; N-dimethylformamide base) propyl group, 1; 1-phenylbenzene-3-(N, N-diethylin) propyl group, 3-acetoxyl group propyl group, isobutyl-, the tertiary butyl, cyclobutyl, 1-methyl cyclobutyl, tert-pentyl, cyclopentyl, cyclohexyl, 1-methylcyclohexyl, phenyl, p-methylphenyl, o-methyl-phenyl-, 2; 4; 6-tri-tert phenyl, m-nitro base, 2,4-dinitrophenyl, benzyl, 3,4-dimethoxy-benzyl, 2; 4; The 6-trimethyl benzyl, to methoxy-benzyl, 3, the 5-dimethoxy-benzyl, to the last of the ten Heavenly stems oxy-benzyl, to nitrobenzyl, adjacent nitrobenzyl, 3; 4-dimethoxy-6-nitrobenzyl, to bromobenzyl, p-chlorobenzyl, 2; The 4-dichloro benzyl, to cyanic acid benzyl, neighbour-(N, N-dimethylaminomethyl) benzyl, to (dihydroxyl boryl) benzyl, to (phenylazo-) benzyl, to (to the anisole azo-group) benzyl, vinyl, allyl group, 1-adamantyl, isobornyl, cinnamyl, 8-quinolyl, N-hydroxy piperidine-4-base, 1,4-lupetidine-4-base, 2-THP trtrahydropyranyl, isonicotine base, diphenylphosphino, three benzylthios, thiophenyl, ortho-nitrophenyl sulfenyl, 2; 4-dinitrobenzene sulfenyl, 2-nitro-4-anisole sulfenyl, formyl radical, 2-pyridine formyl radical, benzoyl-, to the phenyl benzoyl-, to anisoyl, o-nitrobenzoyl, neighbour's (benzoyloxy methyl) benzoyl-, phthaloyl, ethanoyl, trifluoroacetyl group, 3-phenyl propionyl group, 3-(to phenylor) propionyl group, 3-(ortho-nitrophenyl base) propionyl group, 2-methyl-2-(ortho-nitrophenyl oxygen base) propionyl group, 4-chloro butyryl radicals, isobutyryl, 2; 3-phenylbenzene maleoyl, dithio succinyl, 2-xenyl-2-third oxygen carbonyl, tertbutyloxycarbonyl, carbobenzoxy-(Cbz), allyloxy carbonyl, to the nitro benzyloxycarbonyl, to methoxyl group benzyloxy base carbonyl, N-(p-toluenesulfonyl) aminocarboxyl, N-phenylamino thiocarbonyl, adjacent nitro cinnamoyl, N-acetyl methionyl, phthalimide-based, diethylammonium phosphoryl, diphenylphosphine acyl group, dibenzyl phosphoryl, methyl sulphonyl, benzenesulfonyl, to the Methyl benzenesulfonyl base, to anisole alkylsulfonyl, 2,4,6-Three methyl Benzene alkylsulfonyl, trifluoromethyl sulfonyl, benzene methylsulfonyl, to methylbenzene methylsulfonyl and phenacyl-alkylsulfonyl etc.
" pharmacy acceptable salt " of formula I compound of the present invention is meant formula I compound and mineral acid, organic acid or the formed salt of organic protonic acid with basic nitrogen atom.
" steric isomer " of formula I compound of the present invention; Be meant that there is unsymmetrical carbon in formula I compound of the present invention; Carbon-carbon double bond etc.; Its all enantiomers, diastereomer, racemization isomer, cis-trans-isomer, tautomer and composition thereof include in the present invention.
Formula I compound of the present invention, its pharmacy acceptable salt or its isomer can be processed pharmaceutically acceptable pharmaceutical prepn with one or more pharmaceutical carriers, are applied to the patient who needs this treatment with modes such as oral, parenterals.During oral administration, can process conventional solid preparation with the weighting agent of routine, tackiness agent, disintegrating agent, lubricant, thinner etc., like tablet, capsule, pill, granule etc.; When being used for administered parenterally, can be made into injection, comprise injection liquid, injectable sterile powder and concentrated solution for injection.When processing injection, can adopt the conventional method production in the existing pharmaceutical field, during the preparation injection, can not add additives, also can add suitable additives based on the character of medicine.
The present invention also provides formula I compound, its pharmacy acceptable salt or its isomer to treat and/or prevent the application in the medicine of the proliferative disease that lipase and/or PI3-kinases-dependency protein kinase, particularly PI3 kinases and/or mTOR active inhibition is had response in preparation.
Depend on the disease or the disorder of lipase and/or PI3-kinases-dependency protein kinase activity, for example proliferative, inflammatory or anaphylactic disease are perhaps followed usually and are transplanted the disorder that takes place, and are preferred for the treatment of proliferative disease.
Described proliferative disease is selected from optimum or tumorigenesis, lymphatic cancer, breast cancer or the white blood disease of malignant tumour, the cancer of the brain, kidney, liver cancer, adrenal carcinoma, mastocarcinoma, cancer of the stomach, gastric tumor, ovarian cancer, colorectal carcinoma, the rectum cancer, prostate cancer, carcinoma of the pancreas, lung cancer, carcinoma of vagina or thyroid carcinoma, sarcoma, glioblastoma, multiple myeloma or gastrointestinal cancer, especially colorectal carcinoma or colorectal carcinoma or head and neck tumour, hyperproliferative epidermal, psoriatic, hyperplasia of prostate, tumorigenesis, epithelial character.Other disease comprise examine step on syndromes, Lhermitte-Dudos disease and Bannayan-zonana syndrome or wherein PI3K/PKB and mTOR path by the disease of abnormal activation.
4, embodiment
The specific embodiment of form is described in further detail foregoing of the present invention by the following examples.But should this scope that is interpreted as the above-mentioned theme of the present invention only not limited to following examples.
Embodiment 19 (6-methoxypyridine 3-yl)-3-methyl isophthalic acid-(piperidin-4-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines also
The preparation of-2 (1H)-ketone (compound 1)
(1) 4-chloro-6-(6-methoxypyridine 3-yl)-1, the preparation of 5-naphthyridines 3-carboxylic acid, ethyl ester
With 4,6-two chloro-1,5-naphthyridines-3-carboxylic acid, ethyl ester (0.472g, 1.74mmol), 6-(methoxyl group) pyridine-3 ylboronic acid (0.535g, 3.5mmol), Pd (PPh
3)
2Cl
2(0.119g, 0.17mmol) and K
2CO
3(0.718g 5.2mmol) joins in dioxane (10mL) and the water (5mL) successively, substitutes nitrogen, and 90 ℃ of reactions of tube sealing 4h adds shrend and goes out, dichloromethane extraction, and drying, column chromatography gets product 0.373g, yield 62.4%.
(2) 4-[1-(tertbutyloxycarbonyl) piperidin-4-yl is amino]-6-(6-methoxypyridine-3-yl)-1, the preparation of 5-naphthyridines-3-carboxylic acid, ethyl ester
(2.0g 10mmol) joins 4-chloro-6-(6-methoxypyridine-3-yl)-1, and (2.407g is in 30mL ethanolic soln 7.0mmol) for 5-naphthyridines-3-carboxylic acid, ethyl ester with 4-amino piperidine-1-carboxylic acid tert-butyl ester; Be heated to backflow, reaction 12h revolves dried solvent; Add 5mL water, ethyl acetate extraction, drying; Concentrate, column chromatography gets product 3.02g, yield 85.0%.
(3) preparation of 4-[3-formyl radical-6-(6-methoxypyridine-3-yl)-1,5-naphthyridines-4-base is amino] piperidines-1-carboxylic acid tert-butyl ester
In the exsiccant reaction flask, with 4-[1-(tertbutyloxycarbonyl) piperidin-4-yl is amino]-6-(6-methoxypyridine-3-yl)-1 that the last step obtains, (3.02g 5.95mmol) is dissolved in 25mL CH to 5-naphthyridines-3-carboxylic acid, ethyl ester
2Cl
2In, be cooled to-78 ℃, to the toluene solution of the diisobutyl aluminum hydrogen (DIBAlH) that wherein drips 1M (6.0mL, 6.0mmol), low temperature continues reaction 1h down, adds 2mL methyl alcohol cancellation reaction, water, salt solution repeatedly wash organic phase, drying directly is used for next step.
(4) preparation of 4-[6-(6-methoxypyridine-3-yl)-3-[(methylamino) methyl]-1,5-naphthyridines-4-base is amino] piperidines-1-carboxylic acid tert-butyl ester
The CH of the 4-that the last step was obtained [3-formyl radical-6-(6-methoxypyridine-3-yl)-1,5-naphthyridines-4-base is amino] piperidines-1-carboxylic acid tert-butyl ester
2Cl
2Solution (5.95mmol) adds in 27% methylamine alcohol solution of 1.1mL, adds 1.0mL acetic acid, stir half a hour after, add NaBH (OAc) in batches
3(3.82g 18.0mmol), continues to stir 2 hours, adds the NaBH that it is unnecessary that shrend is gone out (OAc)
3, dichloromethane extraction, drying concentrates, and column chromatography gets product 1.45g, two step yields 50.9%.
(5) preparation of 4-[9-(6-methoxypyridine-3-yl)-3-methyl-2-oxo-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-1 (2H)-yl also] piperidines-1-carboxylic acid tert-butyl ester
In the exsiccant reaction flask, and the adding TRIPHOSGENE 99.5 (0.98g, 3.3mmol), triethylamine (1.68mL; 12.1mmol), be dissolved in the 35mL THF, under-10 ℃, add 4-(6-(6-methoxypyridine-3-yl)-3-((methylamino) methyl)-1; 5-naphthyridines-4-base is amino) (1.45g 3.03mmol), is dissolved in the 25mL THF piperidines-1-carboxylic acid tert-butyl ester, stirs 0.5 hour; Revolve most of THF, use ethyl acetate extraction, with saturated sodium carbonate solution and strong brine washing, organic layer is used anhydrous sodium sulfate drying; Column chromatography purification gets product 1.413g, yield 92.4%.
(6) 9-(6-methoxypyridine-3-yl)-3-methyl isophthalic acid-(piperidin-4-yl)-3, the 4-dihydro-pyrimidin is the preparation of [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also
(1.413g 2.8mmol) is dissolved in 7mL CH to piperidines-1-carboxylic acid tert-butyl ester with 4-[9-(6-methoxypyridine-3-yl)-3-methyl-2-oxo-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-1 (2H)-yl also]
2Cl
2In, add 7mL TFA, stirring at room 30 minutes, revolve dried, preparation liquid phase purifying, product 801mg, yield 70.7%.
Molecular formula: C
22H
24N
6O
2Molecular weight: 404.46 mass spectrums (M+H): 405
Embodiment 2 (R)-1-[1-(2-hydroxyl propionyl group) piperidin-4-yl]-9-(6-methoxypyridine-3-yl)-3-methyl-3, the 4-dihydro is phonetic
Pyridine is the preparation of [5,4-c] [1,5] naphthyridines-2 (1H)-ketone (compound 2) also
(133mg 1.2mmol) is dissolved among the 7mL DMF, adds 2-(7-azo benzotriazole)-N under the room temperature, N, N ' with R-lactic acid; N '-tetramethyl-urea phosphofluoric acid ester (HATU) (456mg, 1.2mmol), 9-(6-methoxypyridine-3-yl)-3-methyl isophthalic acid-(piperidin-4-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1 also; 5] naphthyridines-2 (1H)-ketone (compound 1) (405mg, 1.0mmol), stirred overnight at room temperature is poured in the 5mL water, separates out solid; Filter, drying gets product 223mg, yield 46.8%.
Molecular formula: C
25H
28N
6O
4Molecular weight: 476.53 mass spectrums (M+H): 477
Embodiment 3 9-(6-methoxypyridine-3-yl)-3-methyl isophthalic acid-[4-(piperazine-1-yl)-3-(trifluoromethyl) phenyl]-3, the 4-dihydro is phonetic
Pyridine is the preparation of [5,4-c] [1,5] naphthyridines-2 (1H)-ketone (compound 3) also
(1) 4-[4-[4-(tertbutyloxycarbonyl) piperazine-1-yl]-3-(trifluoromethyl) phenyl amino]-6-(6-methoxypyridine-3-yl)-1, the preparation of 5-naphthyridines-3-carboxylic acid, ethyl ester
(2) in the concrete operations reference implementation example 1, throw 4-[4-amino-2-(trifluoromethyl) phenyl] piperazine-1-carboxylic acid tert-butyl ester (3.799g, 11mmol), 4-chloro-6-(6-methoxypyridine-3-yl)-1; 5-naphthyridines-3-carboxylic acid, ethyl ester (2.5g; 7.27mmol), get product 3.31g, yield 69.8%.
(2) preparation of 4-[4-[3-formyl radical-6-(6-methoxypyridine-3-yl)-1,5-naphthyridines-4-base is amino]-2-(trifluoromethyl) phenyl] piperazine-1-carboxylic acid tert-butyl ester
4-[4-[4-(tertbutyloxycarbonyl) piperazine-1-yl]-3-(trifluoromethyl) phenyl amino]-6-(6-methoxypyridine-3-yl)-1 is thrown in (3) in the concrete operations reference implementation example 1, and (3.31g 5.07mmol), directly is used for next step to 5-naphthyridines-3-carboxylic acid, ethyl ester.
(3) preparation of 4-[4-[6-(6-methoxypyridine-3-yl)-3-[(methylamino) methyl]-1,5-naphthyridines-4-base is amino]-2-(trifluoromethyl) phenyl] piperidines-1-carboxylic acid tert-butyl ester
(4) in the concrete operations reference implementation example 1; Throw 4-[4-[3-formyl radical-6-(6-methoxypyridine-3-yl)-1; 5-naphthyridines-4-base is amino]-2-(trifluoromethyl) phenyl] dichloromethane solution (5.07mmol) of piperazine-1-carboxylic acid tert-butyl ester, product 1.871g, two step yields 59.2%.
(4) preparation of 4-[4-[9-(6-methoxypyridine-3-yl)-3-methyl-2-oxo-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-1 (2H)-yl also]-2-(trifluoromethyl) phenyl] piperazine-1-carboxylic acid tert-butyl ester
(5) in the concrete operations reference implementation example 1; Throwing 4-[4-[6-(6-methoxypyridine-3-yl)-3-[(methylamino) methyl]-1,5-naphthyridines-4-base is amino]-2-(trifluoromethyl) phenyl] piperidines-1-carboxylic acid tert-butyl ester (1.871g, 3.0mmol); Get product 1.80g, yield 92.3%.
(5) 9-(6-methoxypyridine-3-yl)-3-methyl isophthalic acid-[4-(piperazine-1-yl) 3-(trifluoromethyl) phenyl]-3, the 4-dihydro-pyrimidin is the preparation of [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also
(6) in the concrete operations reference implementation example 1; Throwing 4-[4-[9-(6-methoxypyridine-3-yl)-3-methyl-2-oxo-3, the 4-dihydro-pyrimidin is [5,4-c] [1 also; 5] naphthyridines-1 (2H)-yl]-2-(trifluoromethyl) phenyl] piperazine-1-carboxylic acid tert-butyl ester (1.80g; 2.77mmol), get product 1.134g, yield 74.5%.
Molecular formula: C
28H
26F
3N
7O
2Molecular weight: 549.55 mass spectrums (M+H): 550
Embodiment 4 1-[1-(2-hydroxyacetyl) piperidin-4-yl]-9-(6-methoxypyridine-3-yl)-3-methyl-3, the 4-dihydro-pyrimidin also
The preparation of [5,4-c] [1,5] naphthyridines-2 (1H)-ketone (compound 5)
Concrete operations reference implementation example 2, throw the 2-oxyacetic acid (91mg, 1.2mmol), HATU (456mg; 1.2mmol), 9-(6-methoxypyridine-3-yl)-3-methyl isophthalic acid-(piperidin-4-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1 also; 5] naphthyridines-2 (1H)-ketone (compound 1) (405mg; 1.0mmol), get product 243mg, yield 52.5%.
Molecular formula: C
24H
26N
6O
4Molecular weight: 462.50 mass spectrums (M+H): 463
Embodiment 52-hydroxy-n-[[9-(6-methoxypyridine-3-yl)-3-methyl-2-oxygen-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] also for 6-
Naphthyridines-1 (2H)-yl]-4-(trifluoromethyl) pyridin-3-yl] preparation of propionic acid amide (compound 8)
(1) 4-[5-(t-butoxycarbonyl amino)-4-(trifluoromethyl) pyridine-2-base is amino]-6-(6-methoxypyridine-3-yl)-1, the preparation of 5-naphthyridines-3-carboxylic acid, ethyl ester
(2) in the concrete operations reference implementation example 1, throw 6-amino-4-(trifluoromethyl) pyridin-3-yl tert-butylamine carbamate (1.802g, 6.5mmol), 4-chloro-6-(6-methoxypyridine-3-yl)-1; 5-naphthyridines-3-carboxylic acid, ethyl ester (1.5g; 4.36mmol), get product 1.812g, yield 71.1%.
(2) preparation of 6-[3-formyl radical-6-(6-methoxypyridine-3-yl)-1,5-naphthyridines-4-base is amino]-4-(trifluoromethyl) pyridin-3-yl amido carboxylic acid tert-butyl ester
4-[5-(t-butoxycarbonyl amino)-4-(trifluoromethyl) pyridine-2-base is amino]-6-(6-methoxypyridine-3-yl)-1 is thrown in (3) in the concrete operations reference implementation example 1, and (1.812g 3.1mmol), directly is used for next step to 5-naphthyridines-3-carboxylic acid, ethyl ester.
(3) preparation of 6-[6-(6-methoxypyridine-3-yl)-3-[(methylamino) methyl]-1,5-naphthyridines-4-base is amino]-4-(trifluoromethyl) pyridin-3-yl amido carboxylic acid tert-butyl ester
(4) in the concrete operations reference implementation example 1; Throw 6-[3-formyl radical-6-(6-methoxypyridine-3-yl)-1; 5-naphthyridines-4-base is amino]-dichloromethane solution (3.1mmol) of 4-(trifluoromethyl) pyridin-3-yl amido carboxylic acid tert-butyl ester, product 1.072g, two step yields 62.2%.
(4) preparation of 6-[9-(6-methoxypyridine-3-yl)-3-methyl-2-oxo-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-1 (2H)-yl also]-4-(trifluoromethyl) pyridin-3-yl amido carboxylic acid tert-butyl ester
(5) in the concrete operations reference implementation example 1; Throwing 6-[6-(6-methoxypyridine-3-yl)-3-[(methylamino) methyl]-1,5-naphthyridines-4-base is amino]-4-(trifluoromethyl) pyridin-3-yl amido carboxylic acid tert-butyl ester (1.072g, 1.93mmol); Get product 0.948g, yield 84.5%.
(5) 1-[5-amino-4-(trifluoromethyl) pyridine-2-yl]-9-(6-methoxypyridine-3-yl)-3-methyl-3, the 4-dihydro-pyrimidin is the preparation of [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also
(6) in the concrete operations reference implementation example 1; Throwing 6-[9-(6-methoxypyridine-3-yl)-3-methyl-2-oxo-3, the 4-dihydro-pyrimidin is [5,4-c] [1 also; 5] naphthyridines-1 (2H)-yl)-4-(trifluoromethyl) pyridin-3-yl amido carboxylic acid tert-butyl ester (0.948g; 1.63mmol), get product 0.544g, yield 69.3%.
(6) preparation of 2-hydroxy-n-[6-[9-(6-methoxypyridine 3-yl)-3-methyl-2-oxo-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-1 (2H)-yl also]-4-(trifluoromethyl) pyridin-3-yl] propionic acid amide
Concrete operations reference implementation example 2, throw lactic acid (123mg, 1.36mmol), HATU (517mg; 1.36mmol), 1-[5-amino-4-(trifluoromethyl) pyridine-2-yl]-9-(6-methoxypyridine-3-yl)-3-methyl-3, the 4-dihydro-pyrimidin is [5,4-c] [1 also; 5] naphthyridines-2 (1H)-ketone (0.544mg; 1.13mmol), get product 243mg, yield 38.9%.
Molecular formula: C
26H
22F
3N
7O
4Molecular weight: 553.49 mass spectrums (M+H): 554
Embodiment 6 1-[4-(2-hydroxyl-oxethyl)-3,5-Dimethylcyclohexyl]-9-(6-methoxypyridine 3-yl)-3-methyl-3,4-two
Hydrogen Mi Dingbing [5,4-c]-1, the preparation of 5-naphthyridines-2 (1H)-ketone (compound 9)
(1) 4-(benzamido group)-6-(6-methoxypyridine-3-yl)-1, the preparation of 5-naphthyridines-3-carboxylic acid, ethyl ester
(2) in the concrete operations reference implementation example 1, throw benzylamine (0.932g, 8.7mmol), 4-chloro-6-(6-methoxypyridine-3-yl)-1,5-naphthyridines-3-carboxylic acid, ethyl ester (2.0g, 5.8mmol), must product 1.791g, yield 74.5%.
(2) 4-(benzamido group)-6-(6-methoxypyridine-3-yl)-1, the preparation of 5-naphthyridines-3-formaldehyde
4-(benzamido group)-6-(6-methoxypyridine-3-yl)-1 is thrown in (3) in the concrete operations reference implementation example 1, and (1.791g 4.32mmol), directly is used for next step to 5-naphthyridines-3-carboxylic acid, ethyl ester.
(3) N-benzyl-6-(6-methoxypyridine-3-yl)-3-[(methylamino) methyl]-1, the preparation of 5-naphthyridines-4-amine
4-(benzamido group)-6-(6-methoxypyridine-3-yl)-1 is thrown in (4) in the concrete operations reference implementation example 1, and the dichloromethane solution (4.32mmol) of 5-naphthyridines-3-formaldehyde gets product 0.983g, two step yields 59.0%.
(4) 1-benzyl-9-(6-methoxypyridine-3-yl)-3-methyl-3, the 4-dihydro-pyrimidin is the preparation of [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also
N-benzyl-6-(6-methoxypyridine-3-yl)-3-[(methylamino) methyl]-1 is thrown in (5) in the concrete operations reference implementation example 1, and (0.983g 2.55mmol), gets product 0.934g, yield 89.0% to 5-naphthyridines-4-amine.
(5) 9-(6-methoxypyridine-3-yl)-3-methyl-3, the 4-dihydro-pyrimidin is the preparation of [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also
With 1-benzyl-9-(6-methoxypyridine-3-yl)-3-methyl-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone (0.934g also; 2.27mmol) be dissolved in the 8mL methyl alcohol, add 0.47g 10%Pd-C, under the nitrogen atmosphere, be heated to 50 ℃; Reaction is spent the night, the elimination solid, and filtrating concentrates; Column chromatography gets product 0.357g, yield 48.9%.
(6) 1-[4-(2-hydroxyl-oxethyl)-3,5-Dimethylcyclohexyl]-9-(6-methoxypyridine-3-yl)-3-methyl-3, the 4-dihydro-pyrimidin is [5,4-c]-1 also, the preparation of 5-naphthyridines-2 (1H)-ketone
With 9-(6-methoxypyridine-3-yl)-3-methyl-3, the 4-dihydro-pyrimidin also [5,4-c] [1,5] naphthyridines-2 (1H)-ketone (0.357g 1.11mmol) is dissolved among the 5mL DMSO, adds K
2CO
3(0.455g, 3.3mmol), 4-toluene sulfonic acide [4-(2-hydroxyl-oxethyl)-3,5-Dimethylcyclohexyl] ester (0.548g, 1.6mmol); Room temperature reaction spends the night, and pours in the water, and solid is separated out in cooling; Suction filtration gets solid, and drying gets product 0.258g, yield 47.2%.
Molecular formula: C
27H
33N
5O
4Molecular weight: 491.58 mass spectrums (M+H): 492
Embodiment 7 (R)-1-(2-hydroxyl propionyl group) piperidin-4-yl]-3-methyl-9-(6-picoline 3-yl)-3, the 4-dihydro-pyrimidin
And the preparation of [5,4-c] [1,5] naphthyridines-2 (1H)-ketone (compound 10)
(1) 4-chloro-6-(6-picoline-3-yl)-1, the preparation of 5-naphthyridines-3-carboxylic acid, ethyl ester
(1) in the concrete operations reference implementation example 1 throws 4,6-two chloro-1,5-naphthyridines-3-carboxylic acid, ethyl ester (0.840g, 3.1mmol), 6-picoline-3-boric acid (0.849g, 6.2mmol), product 0.479g, yield 47.1%.
(2) 4-[1-(tertbutyloxycarbonyl) piperidin-4-yl is amino]-6-(6-picoline-3-yl)-1, the preparation of 5-naphthyridines-3-carboxylic acid, ethyl ester
(2) in the concrete operations reference implementation example 1, throw 4-amino piperidine-1-carboxylic acid tert-butyl ester (0.441g, 2.2mmol), 4-chloro-6-(6-picoline-3-yl)-1,5-naphthyridines-3-carboxylic acid, ethyl ester (0.479g, 1.46mmol), must product 0.644g, yield 89.7%.
(3) preparation of 4-[3-formyl radical-6-(6-picoline-3-yl)-1,5-naphthyridines-4-base is amino] piperidines-1-carboxylic acid tert-butyl ester
4-[1-(tertbutyloxycarbonyl) piperidin-4-yl is amino]-6-(6-picoline-3-yl)-1 is thrown in (3) in the concrete operations reference implementation example 1, and (0.644g 1.31mmol), directly is used for next step to 5-naphthyridines-3-carboxylic acid, ethyl ester.
(4) preparation of 4-[3-[(methylamino) methyl]-6-(6-picoline-3-yl)-1,5-naphthyridines-4-base is amino] piperidines-1-carboxylic acid tert-butyl ester
(4) in the concrete operations reference implementation example 1, the dichloromethane solution (1.31mmol) of throwing 4-[3-formyl radical-6-(6-picoline-3-yl)-1,5-naphthyridines-4-base is amino] piperidines-1-carboxylic acid tert-butyl ester gets product 0.327g, two step yields 53.9%.
(5) preparation of 4-[3-methyl-9-(6-picoline-3-yl)-2-oxo-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-1 (2H)-yl also] piperidines-1-carboxylic acid tert-butyl ester
(5) in the concrete operations reference implementation example 1, (0.327g 0.707mmol), gets product 0.325g, yield 94.0% to piperidines-1-carboxylic acid tert-butyl ester to throw 4-[3-[(methylamino) methyl]-6-(6-picoline-3-yl)-1,5-naphthyridines-4-base is amino].
(6) 3-methyl-9-(6-picoline-3-yl)-1-(piperidin-4-yl)-3, the 4-dihydro-pyrimidin is the preparation of [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also
(6) in the concrete operations reference implementation example 1, [3-methyl-9-(6-picoline-3-yl)-2-oxo-3,4-dihydro-pyrimidin also [5 to throw 4-; 4-c] [1,5] naphthyridines-1 (2H)-yl] piperidines-1-carboxylic acid tert-butyl ester (0.325g, 0.665mmol); Get product 0.218g, yield 84.0%.
(7) (R)-and 1-[1-(2-hydroxyl propionyl group) piperidin-4-yl]-3-methyl-9-(6-picoline-3-yl)-3, the 4-dihydro-pyrimidin is the preparation of [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also
Concrete operations reference implementation example 2, throw R-lactic acid (60mg, 0.67mmol), HATU (255mg; 0.67mmol, 3-methyl-9-(6-picoline-3-yl)-1-(piperidin-4-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1 also; 5] naphthyridines-2 (1H)-ketone (218mg; 0.56mmol), get product 127mg, yield 49.2%.
Molecular formula: C
25H
28N
6O
3Molecular weight: 460.53 mass spectrums (M+H): 461
Embodiment 8 (R)-1-[1-(2-hydroxyl propionyl group) piperidin-4-yl]-3-methyl-9-(1H-pyrazolo [3,4-b] pyridine-5-yl)-3,4-
Dihydro-pyrimidin is the preparation of [5,4-c] [1,5] naphthyridines-2 (1H)-ketone (compound 21) also
(1) 4-chloro-6-(1-(4-methoxy-benzyl)-1H-pyrazolo [3,4-b] pyridine-5-yl)-1, the preparation of 5-naphthyridines-3-carboxylic acid, ethyl ester
(1) in the concrete operations reference implementation example 1 throws 4,6-two chloro-1; 5-naphthyridines-3-carboxylic acid, ethyl ester (2.0g, 7.38mmol), 1-(4-methoxy-benzyl)-1H-pyrazolo [3,4-b] pyridine-5-ylboronic acid (4.190g; 14.8mmol), get product 1.474g, yield 42.1%.
(2) 4-[1-(tertbutyloxycarbonyl) piperidin-4-yl is amino]-6-[1-(4-methoxy-benzyl)-1H-pyrazolo [3,4-b] pyridine-5-yl]-1, the preparation of 5-naphthyridines-3-carboxylic acid, ethyl ester
(2) in the concrete operations reference implementation example 1; Throw 4-amino piperidine-1-carboxylic acid tert-butyl ester (0.935g, 4.67mmol), 4-chloro-6-(1-(4-methoxy-benzyl)-1H-pyrazolo [3,4-b] pyridine-5-yl)-1; 5-naphthyridines-3-carboxylic acid, ethyl ester (1.474g; 3.11mmol), get product 1.735g, yield 87.5%.
(3) preparation of 4-[3-formyl radical-6-[1-(4-methoxy-benzyl)-1H-pyrazolo [3,4-b] pyridine-5-yl]-1,5-naphthyridines-4-base is amino] piperidines-1-carboxylic acid tert-butyl ester
(3) in the concrete operations reference implementation example 1; Throw 4-[1-(tertbutyloxycarbonyl) piperidin-4-yl is amino]-6-[1-(4-methoxy-benzyl)-1H-pyrazolo [3,4-b] pyridine-5-yl]-1,5-naphthyridines-3-carboxylic acid, ethyl ester (1.735g; 2.72mmol), directly be used for next step.
(4) preparation of 4-[6-[1-(4-methoxy-benzyl)-1H-pyrazolo [3,4-b] pyridine-5-yl]-3-[(methylamino) methyl]-1,5-naphthyridines-4-base is amino] piperidines-1-carboxylic acid tert-butyl ester
(4) in the concrete operations reference implementation example 1; Throw the dichloromethane solution (2.72mmol) of 4-[3-formyl radical-6-[1-(4-methoxy-benzyl)-1H-pyrazolo [3,4-b] pyridine-5-yl]-1,5-naphthyridines-4-base is amino] piperidines-1-carboxylic acid tert-butyl ester; Get product 0.785g, two step yields 47.4%.
(5) preparation of 4-[9-[1-(4-methoxy-benzyl)-1H-pyrazolo [3,4-b] pyridine-5-yl]-3-methyl-2-oxo-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-1 (2H)-yl also] piperidines-1-carboxylic acid tert-butyl ester
4-[6-[1-(4-methoxy-benzyl)-1H-pyrazolo [3,4-b] pyridine-5-yl]-3-[(methylamino) methyl]-1 is thrown in (5) in the concrete operations reference implementation example 1; 5-naphthyridines-4-base is amino] piperidines-1-carboxylic acid tert-butyl ester (0.785g; 1.29mmol), get product 0.717g, yield 87.6%.
(6) 3-methyl isophthalic acid-(piperidin-4-yl)-9-(1H-pyrazolo [3,4-b] pyridine-5-yl)-3, the 4-dihydro-pyrimidin is the preparation of [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also
[9-[1-(4-methoxy-benzyl)-1H-pyrazolo [3,4-b] pyridine-5-yl]-3-methyl-2-oxo-3,4-dihydro-pyrimidin also [5 with 4-; 4-c] [1,5] naphthyridines-1 (2H)-yl] (0.717g 1.13mmol) joins among the 15mL TFA piperidines-1-carboxylic acid tert-butyl ester; Stirring at room 3 days is revolved dried solvent, preparation liquid phase purifying; Get product 239mg, yield 51.0%.
(7) (R)-and 1-[1-(2-hydroxyl propionyl group) piperidin-4-yl]-3-methyl-9-(1H-pyrazolo [3,4-b] pyridine-5-yl)-3, the 4-dihydro-pyrimidin is the preparation of [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also
Concrete operations reference implementation example 2, throw R-lactic acid (62mg, 0.69mmol), HATU (262mg; 0.69mmol), 3-methyl isophthalic acid-(piperidin-4-yl)-9-(1H-pyrazolo [3,4-b] pyridine-5-yl)-3,4-dihydro-pyrimidin also [5; 4-c] and [1,5] naphthyridines-2 (1H)-ketone (239mg, 0.577mmol); Get product 153mg, yield 54.5%.
Molecular formula: C
25H
26N
8O
3Molecular weight: 486.53 mass spectrums (M+H): 487
With reference to aforesaid method, can also prepare following compound:
And compound shown in the following formula:
Substituent R in above-mentioned formula (I-1), formula (I-2), the formula (I-3)
1, be respectively following group:
And compound shown in the following formula:
Substituent R in above-mentioned formula (I-4), formula (I-5), formula (I-6), (I-7), formula (I-8), the formula (I-9)
1, be respectively following group:
Claims (9)
1. the compound shown in the general formula (I), its pharmacy acceptable salt or its steric isomer:
Wherein
X is a Sauerstoffatom, sulphur atom, or NR
15
A is a nitrogen-atoms, or CR
7
B is a nitrogen-atoms, or CR
8
R
1Be Wasserstoffatoms, or be not substituted or choose wantonly by 1-5 R
9Substituted C
1-6Alkyl, C
3-8Naphthenic base, C
3-8Thiazolinyl, C
3-8Alkynyl, aryl, heterocyclic radical;
R
2Be Wasserstoffatoms, or be not substituted or choose wantonly by 1-5 R
9Substituted C
1-6Alkyl, C
3-8Naphthenic base, C
2-8Thiazolinyl, C
2-8Alkynyl, aryl, heterocyclic radical;
R
3Be Wasserstoffatoms, hydroxyl, carboxyl ,-(CH
2)
nNR
10aR
10b,-(CH
2)
nC (O) R
11,-(CH
2)
nS (O)
mR
11,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11,-(CH
2)
nC (O) (CH
2)
nNR
10aR
10b,-(CH
2)
nOC (O) R
11,-(CH
2)
nC (O) OR
11,-(CH
2)
nNR
10aC (O) R
11,-(CH
2)
nNR
10aC (O) NR
10aR
10b, or be not substituted or choose wantonly individual halogen atom, hydroxyl, the substituted C of carboxyl substituent of being selected from by 1-3
1-6Alkyl, C
1-6Alkoxyl group;
R
4, R
6Be Wasserstoffatoms independently respectively, or be not substituted or choose wantonly by 1-3 R
9Substituted C
1-6Alkyl, or R
4And R
6Be interconnected to form C
3-8Naphthenic base or heterocyclic radical;
R
5Be Wasserstoffatoms ,-(CH
2)
nS (O)
mR
11, or be not substituted or choose wantonly by 1-3 R
9Substituted C
1-6Alkyl;
R
7, R
8Independently be Wasserstoffatoms respectively, halogen atom, cyanic acid, hydroxyl, carboxyl ,-(CH
2)
nNR
10aR
10b,-(CH
2)
nC (O) R
11,-(CH
2)
nS (O)
mR
11,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11,-(CH
2)
nC (O) (CH
2)
nNR
10aR
10b,-(CH
2)
nOC (O) R
11,-(CH
2)
nC (O) OR
11,-(CH
2)
nNR
10aC (O) R
11,-(CH
2)
nNR
10aC (O) NR
10aR
10b, or be not substituted or choose wantonly individual halogen atom, hydroxyl, the substituted C of carboxyl substituent of being selected from by 1-3
1-6Alkyl, C
1-6Alkoxyl group;
R
9Be halogen atom, hydroxyl, cyanic acid, carboxyl ,-(CH
2)
nNR
10aR
10b,-(CH
2)
nC (O) R
11,-(CH
2)
nS (O)
mR
11,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11,-(CH
2)
nC (O) (CH
2)
nNR
10aR
10b,-(CH
2)
nOC (O) R
11,-(CH
2)
nC (O) OR
11,-(CH
2)
nNR
10aC (O) R
11,-(CH
2)
nNR
10aC (O) NR
10aR
10b, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
2-8Thiazolinyl, C
2-8Alkynyl, C
1-6Alkoxyl group, C
3-8Naphthenic base, aryl, heterocyclic radical;
R
10a, R
10bBe Wasserstoffatoms independently respectively, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
3-8Naphthenic base, aryl, heterocyclic radical;
R
11For not being substituted or choosing wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-8Naphthenic base, aryl, heterocyclic radical;
R
12Be hydroxyl, halogen atom, cyanic acid, trifluoromethyl, C
1-6Alkyl, C
2-8Thiazolinyl, C
2-8Alkynyl, C
1-6Alkoxyl group, C
3-8Naphthenic base, aryl, heterocyclic radical ,-(CH
2)
nNR
13aR
13b,-(CH
2)
nC (O) R
14,-(CH
2)
nC (O) NR
13aR
13b,-(CH
2)
nS (O)
mR
14,-(CH
2)
nS (O)
mNR
13aR
13b,-(CH
2)
nNR
13aS (O)
mR
14,-(CH
2)
nOC (O) R
14,-(CH
2)
nNR
13aC (O) R
14, or-(CH
2)
nNR
13aC (O) NR
13aR
13b
R
13a, R
13bIndependently be Wasserstoffatoms respectively, C
1-6Alkyl, C
3-8Naphthenic base, aryl, or heterocyclic radical;
R
14Be C
1-6Alkyl, C
3-8Naphthenic base, aryl, or heterocyclic radical;
R
15Be Wasserstoffatoms, or C
1-6Alkyl;
M is 1 or 2;
N is 0～4.
2. compound as claimed in claim 1, its pharmacy acceptable salt or its steric isomer:
Wherein
X is a Sauerstoffatom;
A is CR
7
B is CR
8
R
1For not being substituted or choosing wantonly by 1-3 R
9Substituted C
1-6Alkyl, C
3-8Naphthenic base, aryl, 4-10 unit heterocyclic radical;
R
2For not being substituted or choosing wantonly by 1-3 R
9Substituted C
1-6Alkyl, C
3-8Naphthenic base, aryl, 4-10 unit heterocyclic radical;
R
3Be Wasserstoffatoms ,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11, or be not substituted or choose wantonly individual halogen atom, hydroxyl, the substituted C of carboxyl substituent of being selected from by 1-3
1-6Alkyl, C
1-6Alkoxyl group;
R
4, R
6Be Wasserstoffatoms independently respectively, or be not substituted or choose wantonly by 1-3
9Substituted C
1-6Alkyl, or R
4With R
6Be interconnected to form C
3-6Naphthenic base or 3～7 yuan of saturated heterocyclic radicals;
R
5Be Wasserstoffatoms, or be not substituted or choose wantonly by 1-3 R
9Substituted C
1-6Alkyl;
R
7, R
8Independently be Wasserstoffatoms respectively ,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11, or be not substituted or choose wantonly individual halogen atom, hydroxyl, the substituted C of carboxyl substituent of being selected from by 1-3
1-6Alkyl, C
1-6Alkoxyl group;
R
9Be halogen atom, hydroxyl ,-(CH
2)
nNR
10aR
10b,-(CH
2)
nC (O) R
11,-(CH
2)
nS (O)
mR
11,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11,-(CH
2)
nC (O) (CH
2)
nNR
10aR
10b,-(CH
2)
nOC (O) R
11,-(CH
2)
nC (O) OR
11,-(CH
2)
nNR
10aC (O) R
11,-(CH
2)
nNR
10aC (O) NR
10aR
10b, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-8Naphthenic base, aryl, 4-10 unit heterocyclic radical;
R
10a, R
10bBe Wasserstoffatoms independently respectively, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-6Alkyl;
R
11For not being substituted or choosing wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-8Naphthenic base, aryl, 4-10 unit heterocyclic radical;
R
12Be hydroxyl, halogen atom, cyanic acid, trifluoromethyl, C
1-6Alkyl, C
2-8Thiazolinyl, C
2-8Alkynyl, C
1-6Alkoxyl group, C
3-8Naphthenic base, aryl, 4-10 unit heterocyclic radical, or-(CH
2)
nNR
13aR
13b
R
13a, R
13bIndependently be Wasserstoffatoms respectively, C
1-6Alkyl, C
3-8Naphthenic base, aryl, or 4-10 unit heterocyclic radical;
M is 1 or 2;
N is 0～4.
3. compound as claimed in claim 2, its pharmacy acceptable salt or its steric isomer:
Wherein
X is a Sauerstoffatom;
A is CR
7
B is CR
8
R
1For not being substituted or choosing wantonly by 1-3 R
9Substituted C
1-6Alkyl, C
3-7Naphthenic base, phenyl, naphthyl, 5-10 unit heterocyclic radical;
R
2For not being substituted or choosing wantonly by 1-3 R
9Substituted phenyl, naphthyl, 5-10 unit heterocyclic radical;
R
3, R
4, R
6, R
7, R
8Be respectively Wasserstoffatoms;
R
5Be Wasserstoffatoms, or be not substituted or choose wantonly by 1-3 R
9Substituted C
1-6Alkyl;
R
9Be halogen atom, hydroxyl ,-(CH
2)
nNR
10aR
10b,-(CH
2)
nC (O) R
11,-(CH
2)
nS (O)
mR
11,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11,-(CH
2)
nC (O) (CH
2)
nNR
10aR
10b,-(CH
2)
nOC (O) R
11,-(CH
2)
nC (O) OR
11,-(CH
2)
nNR
10aC (O) R
11,-(CH
2)
nNR
10aC (O) NR
10aR
10b, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-7Naphthenic base, phenyl, 5-10 unit heterocyclic radical;
R
10a, R
10bBe Wasserstoffatoms independently respectively, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-6Alkyl;
R
11For not being substituted or choosing wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-7Naphthenic base, phenyl, 5-10 unit heterocyclic radical;
R
12Be hydroxyl, halogen atom, cyanic acid, trifluoromethyl, C
1-6Alkyl, C
1-6Alkoxyl group, C
3-7Naphthenic base, phenyl, 5-10 unit heterocyclic radical, or-(CH
2)
nNR
13aR
13b
R
13a, R
13bIndependently be Wasserstoffatoms respectively, C
1-6Alkyl, C
3-7Naphthenic base, phenyl, or 5-10 unit heterocyclic radical;
M is 1 or 2;
N is 0～3.
4. compound as claimed in claim 3, its pharmacy acceptable salt or its steric isomer:
Wherein
X is a Sauerstoffatom;
A is CR
7
B is CR
8
R
1For not being substituted or choosing wantonly by 1-3 R
9Substituted cyclopentyl, cyclohexyl, phenyl, naphthyl, piperidyl, piperazinyl, imidazolidyl, pyrazolidyl, tetrahydrofuran base, morpholinyl, pyridyl, pyrimidyl, pyrazolyl, indazolyl, quinolyl, indyl, Pyrazolopyridine base;
R
2For not being substituted or choosing wantonly by 1-3 R
9Substituted phenyl, pyridyl, pyrimidyl, pyrazolyl, indazolyl, quinolyl, indyl, Pyrazolopyridine base;
R
3, R
4, R
6, R
7, R
8Be respectively Wasserstoffatoms;
R
5Be Wasserstoffatoms, or be not substituted or choose wantonly by 1-3 R
9Substituted C
1-6Alkyl;
R
9Be halogen atom, hydroxyl ,-(CH
2)
nNR
10aR
10b,-(CH
2)
nC (O) R
11,-(CH
2)
nS (O)
mR
11,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11,-(CH
2)
nC (O) (CH
2)
nNR
10aR
10b,-(CH
2)
nOC (O) R
11,-(CH
2)
nC (O) OR
11,-(CH
2)
nNR
10aC (O) R
11,-(CH
2)
nNR
10aC (O) NR
10aR
10b, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-6Naphthenic base, 5-7 unit heterocyclic radical;
R
10a, R
10bIndependently be Wasserstoffatoms respectively, methyl, or ethyl;
R
11For not being substituted or choosing wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-6Naphthenic base, phenyl, 5-7 unit heterocyclic radical;
R
12Be hydroxyl, fluorine atom, cyanic acid, trifluoromethyl, C
1-6Alkyl, C
1-6Alkoxyl group, or-(CH
2)
nNR
13aR
13b
R
13a, R
13bIndependently be Wasserstoffatoms respectively, methyl, or ethyl;
M is 1 or 2;
N is 0～3.
5. compound as claimed in claim 4, its pharmacy acceptable salt or its steric isomer:
Wherein
X is a Sauerstoffatom;
A is CR
7
B is CR
8
R
1For not being substituted or choosing wantonly by 1-3 R
9Substituted cyclopentyl, cyclohexyl, phenyl, naphthyl, piperidyl, piperazinyl, morpholinyl, pyridyl, pyrimidyl, pyrazolyl, indazolyl, quinolyl, indyl, Pyrazolopyridine base;
R
2For not being substituted or choosing wantonly by 1-3 R
9Substituted phenyl, pyridyl, pyrimidyl, indazolyl, quinolyl, indyl, Pyrazolopyridine base;
R
3, R
4, R
6, R
7, R
8Be respectively Wasserstoffatoms;
R
5Be Wasserstoffatoms, methyl, ethyl, or propyl group;
R
9Be fluorine atom, chlorine atom, hydroxyl ,-(CH
2)
nNR
10aR
10b,-(CH
2)
nC (O) R
11,-(CH
2)
nS (O)
mR
11,-(CH
2)
nS (O)
mNR
10aR
10b,-(CH
2)
nNR
10aS (O)
mR
11,-(CH
2)
nC (O) (CH
2)
nNR
10aR
10b,-(CH
2)
nOC (O) R
11,-(CH
2)
nC (O) OR
11,-(CH
2)
nNR
10aC (O) R
11,-(CH
2)
nNR
10aC (O) NR
10aR
10b, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-6Naphthenic base, piperazinyl, imidazolyl, pyrazolyl, triazolyl;
R
10a, R
10bIndependently be Wasserstoffatoms respectively, methyl, or ethyl;
R
11For not being substituted or choosing wantonly by 1-3 R
12Substituted C
1-6Alkyl, C
1-6Alkoxyl group, C
3-6Naphthenic base, phenyl;
R
12Be hydroxyl, fluorine atom, cyanic acid, trifluoromethyl, C
1-6Alkyl, C
1-6Alkoxyl group, or-(CH
2)
nNR
13aR
13b
R
13a, R
13bIndependently be Wasserstoffatoms respectively, methyl, or ethyl;
M is 1 or 2;
N is 0～3.
6. compound as claimed in claim 5, its pharmacy acceptable salt or its steric isomer:
Wherein
X is a Sauerstoffatom;
A is CR
7
B is CR
8
R
1For not being substituted or choosing wantonly by 1-3 R
9Substituted cyclopentyl, cyclohexyl, phenyl, piperidyl, piperazinyl, morpholinyl, pyridyl, pyrimidyl, indazolyl, quinolyl, indyl, Pyrazolopyridine base;
R
2For not being substituted or choosing wantonly by 1-3 R
9Substituted phenyl, pyridyl, pyrimidyl, indazolyl, quinolyl, indyl, Pyrazolopyridine base;
R
3, R
4, R
6, R
7, R
8Be respectively Wasserstoffatoms;
R
5Be Wasserstoffatoms, methyl, ethyl, or propyl group;
R
9Be fluorine atom, chlorine atom, hydroxyl ,-(CH
2)
nNR
10aR
10b,-(CH
2)
nC (O) R
11,-(CH
2)
nS (O)
mR
11,-(CH
2)
nC (O) (CH
2)
nNR
10aR
10b,-(CH
2)
nOC (O) R
11,-(CH
2)
nC (O) OR
11,-(CH
2)
nNR
10aC (O) R
11,-(CH
2)
nNR
10aC (O) NR
10aR
10b, or be not substituted or choose wantonly by 1-3 R
12Substituted C
1-3Alkyl, C
1-2Alkoxyl group, C
3-6Naphthenic base, piperazinyl, imidazolyl, pyrazolyl;
R
10a, R
10bIndependent respectively is Wasserstoffatoms, methyl, or ethyl;
R
11For not being substituted or choosing wantonly by 1-3 R
12Substituted C
1-4Alkyl, C
1-3Alkoxyl group, phenyl;
R
12Be hydroxyl, fluorine atom, cyanic acid, trifluoromethyl, methyl, ethyl, sec.-propyl, methoxyl group, or oxyethyl group;
M is 1 or 2;
N is 0～2.
7. compound as claimed in claim 6, its pharmacy acceptable salt or its steric isomer, said compound is selected from:
9-(6-methoxypyridine-3-yl)-3-methyl isophthalic acid-(piperidin-4-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also,
(R)-and 1-[1-(2-hydroxyl propionyl group) piperidin-4-yl]-9-(6-methoxypyridine-3-yl)-3-methyl-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also,
9-(6-methoxypyridine-3-yl)-3-methyl isophthalic acid-[4-(piperazine-1-yl)-3-(trifluoromethyl) phenyl]-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also,
2-[4-[9-(6-methoxypyridine-3-yl)-3-methyl-2-oxo-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-1 (2H)-yl also] phenyl]-2-methyl propionitrile,
1-[1-(2-hydroxyl propionyl group) piperidin-4-yl]-9-(6-methoxypyridine-3-yl)-3-methyl-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also,
4-[9-(6-methoxypyridine-3-yl)-3-methyl-2-oxo-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-1 (2H)-yl also] piperidines-1-carboxylate methyl ester,
1-(1-ethanoyl piperidin-4-yl)-9-(6-methoxypyridine-3-yl)-3-methyl-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also,
2-hydroxy-n-[6-[9-(6-methoxypyridine-3-yl)-3-methyl-2-oxo-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-1 (2H)-yl also]-4-(trifluoromethyl) pyridin-3-yl] propionic acid amide,
1-[4-(2-hydroxyl-oxethyl)-3,5-Dimethylcyclohexyl]-9-(6-methoxypyridine-3-yl)-3-methyl-3, the 4-dihydro-pyrimidin is [5,4-c]-1 also, 5-naphthyridines-2 (1H)-ketone,
(R)-and 1-[1-(2-hydroxyl propionyl group) piperidin-4-yl]-3-methyl-9-(6-picoline-3-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also,
3-methyl-9-(6-picoline-3-yl)-1-[4-(piperazine-1-yl)-3-(trifluoromethyl) phenyl]-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also,
2-methyl-2-[4-[3-methyl-9-(6-picoline-3-yl)-2-oxo-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-1 (2H)-yl also] phenyl] propionitrile,
1-[1-(2-hydroxyacetyl) piperidin-4-yl]-3-methyl-9-(6-picoline-3-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also,
4-[3-methyl-9-(6-picoline-3-yl)-2-oxo-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-1 (2H)-yl also] piperidines-1-carboxylate methyl ester,
1-(1-ethanoyl piperidin-4-yl)-3-methyl-9-(6-picoline-3-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also,
3-methyl-9-(6-picoline-3-yl)-1-(piperidin-4-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also,
2-hydroxy-n-[6-[3-methyl-9-(6-picoline-3-yl)-2-oxo-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-1 (2H)-yl also]-4-(trifluoromethyl) pyridin-3-yl] propionic acid amide,
1-[4-(2-hydroxyl-oxethyl)-3,5-Dimethylcyclohexyl]-3-methyl-9-(6-picoline-3-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also,
3-methyl isophthalic acid-[4-(piperazine-1-yl)-3-(trifluoromethyl) phenyl]-9-(1H-pyrazolo [3,4-b] pyridine-5-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also,
2-methyl-2-[4-[3-methyl-2-oxo-9-(1H-pyrazolo [3,4-b] pyridine-5-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-1 (2H)-yl also] phenyl] propionitrile,
(R)-and 1-[1-(2-hydroxyl propionyl group) piperidin-4-yl]-3-methyl-9-(1H-pyrazolo [3,4-b] pyridine-5-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also,
1-[1-(2-hydroxyacetyl) piperidin-4-yl]-3-methyl-9-(1H-pyrazolo [3,4-b] pyridine-5-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also,
4-[3-methyl-2-oxo-9-(1H-pyrazolo [3,4-b] pyridine-5-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-1 (2H)-yl also] piperidines-1-carboxylate methyl ester,
1-(1-ethanoyl piperidin-4-yl)-3-methyl-9-(1H-pyrazolo [3,4-b] pyridine-5-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also,
3-methyl isophthalic acid-(piperidin-4-yl)-9-(1H-pyrazolo [3,4-b] pyridine-5-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also,
2-hydroxy-n-[6-[3-methyl-2-oxo-9-(1H-pyrazolo [3,4-b] pyridine-5-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-1 (2H)-yl also]-4-(trifluoromethyl) pyridin-3-yl] propionic acid amide and
1-[4-(2-hydroxyl-oxethyl)-3,5-Dimethylcyclohexyl]-3-methyl-9-(1H-pyrazolo [3,4-b] pyridine-5-yl)-3, the 4-dihydro-pyrimidin is [5,4-c] [1,5] naphthyridines-2 (1H)-ketone also.
8. contain the pharmaceutical prepn of each described compound of claim 1～7, its pharmacy acceptable salt or its steric isomer, it is characterized in that comprising one or more pharmaceutical carriers.
9. each described compound of claim 1～7, its pharmacy acceptable salt or its steric isomer treat and/or prevent the application in the medicine of the proliferative disease that lipase and/or PI3-kinases-dependency protein kinase, particularly PI3 kinases and/or the active inhibition of mTOR is had response in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102824065A CN102399220A (en) | 2010-09-15 | 2010-09-15 | Tricyclic dual PI3K and mTOR inhibitors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102824065A CN102399220A (en) | 2010-09-15 | 2010-09-15 | Tricyclic dual PI3K and mTOR inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102399220A true CN102399220A (en) | 2012-04-04 |
Family
ID=45881923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102824065A Pending CN102399220A (en) | 2010-09-15 | 2010-09-15 | Tricyclic dual PI3K and mTOR inhibitors |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102399220A (en) |
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013071698A1 (en) * | 2011-11-17 | 2013-05-23 | 山东轩竹医药科技有限公司 | Three-ring pi3k and/or mtor inhibitor |
| WO2014040373A1 (en) * | 2012-09-12 | 2014-03-20 | 山东轩竹医药科技有限公司 | Pi3k and/or mtor inhibitor |
| WO2014154026A1 (en) * | 2013-03-28 | 2014-10-02 | 山东轩竹医药科技有限公司 | PI3K AND/OR mTOR INHIBITOR PRODRUG |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9533954B2 (en) | 2010-12-22 | 2017-01-03 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| US9533984B2 (en) | 2013-04-19 | 2017-01-03 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| US9708318B2 (en) | 2015-02-20 | 2017-07-18 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9890156B2 (en) | 2015-02-20 | 2018-02-13 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US10611762B2 (en) | 2017-05-26 | 2020-04-07 | Incyte Corporation | Crystalline forms of a FGFR inhibitor and processes for preparing the same |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
| US11407750B2 (en) | 2019-12-04 | 2022-08-09 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
-
2010
- 2010-09-15 CN CN2010102824065A patent/CN102399220A/en active Pending
Cited By (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10213427B2 (en) | 2010-12-22 | 2019-02-26 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| US10813930B2 (en) | 2010-12-22 | 2020-10-27 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| US9533954B2 (en) | 2010-12-22 | 2017-01-03 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| WO2013071698A1 (en) * | 2011-11-17 | 2013-05-23 | 山东轩竹医药科技有限公司 | Three-ring pi3k and/or mtor inhibitor |
| US20150166539A1 (en) * | 2011-11-17 | 2015-06-18 | Xuanzhu Pharma Co., Ltd. | Three-ring pi3k and/or mtor inhibitor |
| CN103224496A (en) * | 2011-11-17 | 2013-07-31 | 山东轩竹医药科技有限公司 | Tricyclic PI3K and/or mTOR inhibitors |
| US9284315B2 (en) | 2011-11-17 | 2016-03-15 | Zuanzhu Pharma Co., Ltd. | Three-ring PI3K and/or mTOR inhibitor |
| CN103224496B (en) * | 2011-11-17 | 2016-06-29 | 山东轩竹医药科技有限公司 | Tricyclic antidepressants PI3K and/or mTOR inhibitors |
| US10131667B2 (en) | 2012-06-13 | 2018-11-20 | Incyte Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| US11053246B2 (en) | 2012-06-13 | 2021-07-06 | Incyte Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| US11840534B2 (en) | 2012-06-13 | 2023-12-12 | Incyte Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| US9745311B2 (en) | 2012-08-10 | 2017-08-29 | Incyte Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| CN104884456A (en) * | 2012-09-12 | 2015-09-02 | 山东轩竹医药科技有限公司 | Pi3k and/or mtor inhibitor |
| US9365572B2 (en) * | 2012-09-12 | 2016-06-14 | Xuanzhu Pharma Co., Ltd. | PI3K and/or mTOR inhibitor |
| JP2015531779A (en) * | 2012-09-12 | 2015-11-05 | 山東軒竹医薬科技有限公司 | PI3K and / or mTOR inhibitors |
| CN104884456B (en) * | 2012-09-12 | 2017-08-11 | 山东轩竹医药科技有限公司 | PI3K and/or mTOR inhibitors |
| US20150239885A1 (en) * | 2012-09-12 | 2015-08-27 | Xuanzhu Pharma Co., Ltd. | Pi3k and/or mtor inhibitor |
| WO2014040373A1 (en) * | 2012-09-12 | 2014-03-20 | 山东轩竹医药科技有限公司 | Pi3k and/or mtor inhibitor |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| CN105121442A (en) * | 2013-03-28 | 2015-12-02 | 山东轩竹医药科技有限公司 | PI3K and/or mTOR inhibitor prodrug |
| CN105121442B (en) * | 2013-03-28 | 2017-05-17 | 山东轩竹医药科技有限公司 | PI3K and/or mTOR inhibitor prodrug |
| WO2014154026A1 (en) * | 2013-03-28 | 2014-10-02 | 山东轩竹医药科技有限公司 | PI3K AND/OR mTOR INHIBITOR PRODRUG |
| US10040790B2 (en) | 2013-04-19 | 2018-08-07 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US10450313B2 (en) | 2013-04-19 | 2019-10-22 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US9533984B2 (en) | 2013-04-19 | 2017-01-03 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US10947230B2 (en) | 2013-04-19 | 2021-03-16 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11530214B2 (en) | 2013-04-19 | 2022-12-20 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US10738048B2 (en) | 2015-02-20 | 2020-08-11 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US11014923B2 (en) | 2015-02-20 | 2021-05-25 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US10632126B2 (en) | 2015-02-20 | 2020-04-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US10251892B2 (en) | 2015-02-20 | 2019-04-09 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9708318B2 (en) | 2015-02-20 | 2017-07-18 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9801889B2 (en) | 2015-02-20 | 2017-10-31 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US10214528B2 (en) | 2015-02-20 | 2019-02-26 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US11667635B2 (en) | 2015-02-20 | 2023-06-06 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US10016438B2 (en) | 2015-02-20 | 2018-07-10 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US11173162B2 (en) | 2015-02-20 | 2021-11-16 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9890156B2 (en) | 2015-02-20 | 2018-02-13 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US10611762B2 (en) | 2017-05-26 | 2020-04-07 | Incyte Corporation | Crystalline forms of a FGFR inhibitor and processes for preparing the same |
| US11472801B2 (en) | 2017-05-26 | 2022-10-18 | Incyte Corporation | Crystalline forms of a FGFR inhibitor and processes for preparing the same |
| US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
| US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11407750B2 (en) | 2019-12-04 | 2022-08-09 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102399220A (en) | Tricyclic dual PI3K and mTOR inhibitors | |
| CN102399233B (en) | Dual PI3K and mTOR inhibitor compounds | |
| KR102007056B1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases | |
| JP6355648B2 (en) | 3- (Benzimidazol-2-yl) -indazole inhibitors of WNT signaling pathway and their therapeutic use | |
| TWI527800B (en) | 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof | |
| KR100441362B1 (en) | Phthalazines with Angiogenesis Inhibiting Activity | |
| RU2559895C2 (en) | Nitrogen-containing heteroaryl derivatives | |
| CA2409743C (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | |
| WO2020249079A1 (en) | Shp2 phosphatase allosteric inhibitor | |
| JP6564406B2 (en) | Imidazo-pyridazine derivatives as casein kinase 1 delta / epsilon inhibitors | |
| CN101790527A (en) | The kinase whose benzothiophene inhibitors of RHO | |
| CA2905751A1 (en) | Novel compounds and compositions for inhibition of fasn | |
| CN102361859A (en) | Heteroaryl compounds useful as Raf kinase inhibitors | |
| CA2784393A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| JP2010209121A (en) | New pyridopyrazine and use thereof as kinase modulator | |
| CN102159573A (en) | Pyrazolo pyridine derivatives as nadph oxidase inhibitors | |
| WO2016208592A1 (en) | Bicyclic heterocyclic amide derivative | |
| JP2021535213A (en) | Tetrahydropyridopyrimidine derivative as an AhR modulator | |
| JP2021503013A (en) | ACSS2 Inhibitor and How to Use It | |
| CN107056755B (en) | Five-ring heterocycles amides WNT pathway inhibitor | |
| CN104837844A (en) | Pyrazole substituted imidazopyrzines as casein kinase 1D/E inhibitors | |
| JP2010505922A (en) | Novel imidazolone derivatives, their production as pharmaceuticals, pharmaceutical compositions and their use as protein kinase inhibitors, in particular as CDC7 inhibitors | |
| TW202104212A (en) | Heterocyclic compounds as kinase inhibitors for therapeutic uses | |
| CN103102352B (en) | Tyrosine kinase inhibitor indolinone derivative | |
| CN103664734B (en) | Heterocycle hydroximic acid compound and medicinal compositions thereof and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG XUANZHU MEDICAL SCI-TECH CO., LTD. Free format text: FORMER OWNER: HUANG ZHENHUA Effective date: 20120723 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20120723 Address after: Tianchen Avenue in Ji'nan high tech Development Zone of Shandong province 250101 City No. 2518 Applicant after: Shandong Xuanzhu Medical Technology Co., Ltd. Address before: Tianchen Avenue in Ji'nan high tech Development Zone of Shandong province 250101 City No. 2518 Applicant before: Huang Zhenhua |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120404 |